Top Industry Leaders in the Turner Syndrome Market
Latest Turner Syndrome Companies Updates:
Novo Nordisk expands access to Norditropin® (somatropin) growth hormone therapy for TS patients in 12 new countries, contributing to improved growth outcomes.
Ovid Therapeutics initiates a Phase 2 clinical trial of their investigational oral therapy, OV101, for treating cognitive deficits and fatigue in women with TS.
Gene editing company Editas Medicine announces encouraging preclinical results using CRISPR technology for potential future genetic correction of TS-causing mutations.
The Turner Syndrome Society of the United States (TSSUS) partners with pharmaceutical companies and research institutions to fund clinical trials and accelerate development of new TS treatments.
The European Society for Human Genetics (ESHG) collaborates with researchers to develop standardized clinical guidelines and improve care for individuals with TS across Europe.
List of Turner Syndrome Key companies in the market:
- Cooper Pharma (India)
- Pfizer Inc. (U.S.)
- Lilly USA, LLC (U.S.)
- Genentech, Inc. (U.S.)
- Novo Nordisk (Denmark)
- Smiths Medical (U.S.)
- Rocket Medical plc. (U.K)
- Medtronic (U.S.)
- Sanofi (France)